Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer

BACKGROUND: The skeletal muscle index (SMI), which is calculated as the ratio of skeletal muscle area at the third lumbar vertebral level divided by height squared, has been considered a prognostic factor in patients with breast cancer. However, the prognostic impact of changes in SMI during treatme...

Descripción completa

Detalles Bibliográficos
Autores principales: Amitani, Masatsugu, Oba, Takaaki, Kiyosawa, Nami, Morikawa, Hiroki, Chino, Tatsunori, Soma, Ai, Shimizu, Tadafumi, Ohno, Koichi, Ono, Mayu, Ito, Tokiko, Kanai, Toshiharu, Maeno, Kazuma, Ito, Ken-ichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962250/
https://www.ncbi.nlm.nih.gov/pubmed/35346102
http://dx.doi.org/10.1186/s12885-022-09443-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8962250/
https://www.ncbi.nlm.nih.gov/pubmed/35346102
http://dx.doi.org/10.1186/s12885-022-09443-1

Ejemplares similares